• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fresenius Kabi, Corvida Medical ink U.S. distribution deal for drug-transfer device

April 2, 2021 By Sean Whooley

Fresenius Kabi HaloFresenius Kabi announced that it entered into a U.S. distribution agreement with Corvida Medical for the HALO closed system drug-transfer device (CSTD).

Under the distribution agreement, Lake Zurich, Ill.-based Fresenius Kabi will be the exclusive U.S. distributor for the HALO CSTD, an airtight and leak-proof CSTD designed to prohibit the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, according to a news release.

Common challenges such as individual and environmental exposure to drug vapor, aerosols and droplets can be minimized during the compounding and administration of hazardous drugs like in chemotherapy through the use of the HALO system.

Financial terms of the distribution agreement were not disclosed. The companies said the deal could be expanded to other territories in the future.

“Fresenius Kabi is committed to offering solutions that provide the safe preparation and delivery of medications across the continuum of care,” Fresenius Kabi USA president & CEO John Ducker said in the release. “CSTDs play a critical role in protecting health care professionals from the risks of exposure to hazardous drugs during the preparation in the pharmacy and during patient administration by nurses. The combination of Fresenius Kabi freeflex/freeflex+ IV solution containers, oncology medicines and Corvida Medical’s HALO CSTD allows Fresenius Kabi to provide customers a broad range of products to assist with their oncology needs.”

“We believe Fresenius Kabi is a great partner for the HALO closed system drug-transfer device,” added Corvida Medical CEO Mitch Moeller. “Their reputation for quality and patient focus along with their commercial infrastructure, distribution experience, customer relationships and extensive product portfolio will help our efforts to make HALO a leading CSTD option for U.S. customers. We are pleased that Fresenius Kabi recognized the design benefits, innovation and quality of the HALO product portfolio.”

Filed Under: Business/Financial News, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Corvida Medical, freseniuskabi

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS